Background Glucose absorption postprandially increases markedly to levels far greater than possible by the classic glucose transporter sodium-glucose cotransporter 1 (SGLT1). Hypothesis Luminal concentrations of glucose >50 mM lead to rapid, phenotypic, non-genomic adaptations by the enterocyte to recruit another transporter, glucose transporter 2 (GLUT2), to the apical membrane to increase glucose absorption. Methods Isolated segments of jejunum were perfused in vivo with glucose-containing solutions in anesthetized rats. Carriermediated glucose uptake was measured in 10 and 100 mM glucose solutions (n=6 rats each) with and without selective inhibitors of SGLT1 and GLUT2. Results The mean rate of carrier-mediated glucose uptake increased in rats perfused with 100 mM versus 10 mM glucose to 13.9±2.9 μmol from 2.1±0.1 μmol, respectively (p<0.0001). Using selective inhibitors, the relative contribution of GLUT2 to glucose absorption was 56% in the 100 mM concentration of glucose compared to the 10 mM concentration (27%; p< 0.01). Passive absorption accounted for 6% of total glucose absorption at 100 mM glucose. Conclusion A small amount of GLUT2 is active at the lesser luminal concentrations of glucose, but when exposed to concentrations of 100 mM, the enterocyte presumably changes its phenotype by recruiting GLUT2 apically to markedly augment glucose absorption.
Introduction
It is accepted widely that glucose absorption across the intestine occurs primarily through a carrier-mediated process by which luminal glucose, after having been broken down from polysaccharides by disaccharidases at the brush border, is transported into the cell by a hexose transporter located in the apical membrane of the enterocyte. [1] [2] [3] [4] The transporter responsible for this carrier-mediated, stereospecific glucose transport has been assumed to be primarily the sodium-dependent glucose transporter, SGLT1; SGLT1, an active transport protein, is powered by the downhill Na + gradient generated by a Na + /K + -ATPase at the basolateral membrane. Several of the more classic physiologic and electrophysiologic studies addressing the mechanism of Na + / glucose co-transport have supported this concept. [5] [6] [7] [8] Once inside the cell, sugar molecules are then transported into the portal venous circulation by the facilitative transporter glucose transporter 2 (GLUT2) located in the basolateral membrane. The role of SGLT1 has become accepted so widely that standard texts have presented SGLT1 as the primary biochemical and physiologic way in which glucose is absorbed across the brush border membrane. 9 This classic explanation, however, fails to explain another component responsible for glucose absorption in vivo that becomes evident at greater luminal concentrations of glucose (>50 mM); this second component appears to be responsible for the majority of glucose absorption early postprandially. 10 Whereas SGLT1 becomes saturated between 10 and 30 mM glucose (the K m of SGLT1 is about 3-6 mM), the other component not explained by simple diffusion does not appear to saturate even at concentrations exceeding 100 mM. [11] [12] [13] Two theories have been proposed to explain the mechanism behind this other component of glucose absorption. The theory of "paracellular flow" or "solvent drag" proposed by Pappenheimer et al. 14 postulates that enterocytes undergo a conformational change in response to a greater luminal concentration of glucose, which opens tight junctions between cells, allowing water into the intercellular space, which then "drags" solute and nutrients along with it, known as solvent drag. 14 A second, more recent theory proposed by Kellett and colleagues 15, 16 suggests that GLUT2, a facilitated transporter, is translocated rapidly from a preformed cytosolic pool to the apical membrane of the enterocyte when luminal glucose concentration exceeds the absorptive capacity of SGLT1 (around 30 mM). 3 Immunocytochemical detection of GLUT2 in the brush border membrane of rat enterocytes and in vivo data lend considerable credibility to this theory. 17 Despite our own inability to show GLUT2-mediated augmentation of glucose uptake into intestinal segments ex vivo by the study of everted sleeves, 4 we have shown the presence of GLUT2 in the apical membrane in human Caco-2 cells and rat RIE cells, both cell culture models of epithelial cells; more importantly, we have demonstrated a marked augmentation of glucose uptake by these cells when exposed to glucose concentrations >25 mM that is sensitive to phloretin, a specific inhibitor of GLUT2. 18 Because of concerns of rapid translocation of GLUT2 out of the apical membrane during ex vivo preparations to study in vitro glucose uptake, 4 we designed the current study with two aims. First, we wanted to determine if glucose absorption in an in vivo rat model of intestinal perfusion would increase when the luminal concentration of glucose was increased to 100 mM. Second, because transportermediated glucose absorption is stereospecific, our aim was to determine if absorption of L-glucose, the stereoisomer of Dglucose, was increased markedly as a function of the opening of tight junctions, a process that would not be stereospecific.
Our hypothesis was that in vivo absorption of glucose after a meal is increased markedly by a stereospecific, carriermediated process secondary to apical GLUT2 and not by a stereo-nonspecific process.
Methods
All experiments were conducted only after approval by our Institutional Animal Care and Use Committee and in accordance with the guidelines of the National Institutes of Health for the humane use and care of laboratory animals.
Design
Our in vivo intestinal perfusion experiments involved comparison of glucose absorption, both stereospecific carrier-mediated and stereo-nonspecific passive absorption, at 10 and 100 mM glucose solutions. We then determined the effect of specific inhibition of the SGLT1-mediated process by phlorizin (Sigma, St. Louis, MO) during 10 and 100 mM glucose perfusions as well as the effect of specific inhibition of the GLUT2-mediated process by phloretin (Sigma) again at 10 and 100 mM glucose perfusions. By measuring absorption of 14 C-D-glucose and 3 H-L-glucose, we were able to determine separately the carrier-mediated ( 14 C) and non-carrier-mediated ( 3 H, diffusion) components of glucose absorption under each condition.
Preparation of In Vivo Model of Perfusion
Male Lewis rats (Harlan, Indianapolis, IN) weighing 250-300 g were fed ad libitum on standard rat chow with free access to water. The rats were allowed to acclimate to the laboratory housing environment for at least 1 week prior to experiments in a 12:12-h dark-light cycle. Rats were anesthetized using 2% inhaled isoflurane for induction followed by intraperitoneal sodium pentobarbital (50 mg/ kg) for maintenance of anesthesia. Using a midline celiotomy, a 30-cm jejunal segment was isolated beginning 5 cm distal to the ligament of Treitz. The proximal and distal ends of this segment were ligated to avoid spillage of enteric contents into the abdomen during the experiment. This 30-cm jejunal segment was then cannulated proximally (I.D.=0.035 in.) and distally (I.D.=0.118 in.) with Silastic® tubing and secured in place with a purse string suture. The segment was perfused initially with 30 ml of Ringer's lactate to evacuate intraluminal content before beginning the infusion of test solutions. Rats were kept on a warmed mat to avoid inducing hypothermia during the perfusion. We studied jejunal glucose uptake in Lewis rats between 8:00 and 11:00 a.m. Adherence to this schedule was undertaken to avoid the known diurnal patterns in hexose transporter expression and function which would confound our results. 19 
Conduct of Experiments
After placement of the perfusion and the effluent catheters, rats were randomized to one of the following six groups of six rats each: group 1, 10 mM glucose; group 2, 100 mM glucose; group 3, 10 mM glucose with 1 mM phlorizin (SGLT1 inhibitor); group 4, 100 mM glucose with 1 mM phlorizin; group 5, 10 mM glucose with 1 mM phloretin (GLUT2 inhibitor); and group 6, 100 mM glucose with 1 mM phloretin. Phlorizin and phloretin were solubilized in 0.3% ethanol. See below for description of test solutions. Doses of phlorizin and phloretin were based on multiple, well-validated previous studies. 4, 10, 20 All experiments were done in anesthetized rats. First, the 30-cm segment of intestine was flushed with 30 ml of Ringer's lactate to evacuate residual intraluminal content. Then, the infusion of the respective warmed (38°C) test solution was begun at a constant rate of 1 ml/min. All effluent from the 30-cm segment was collected at 10-min intervals for 2 h. Prior to beginning our test experiments, we infused solutions with radiolabeled polyethylene glycol ( 3 H-PEG, a nonabsorbable marker) to determine the time it took to reach a steady state. In this model, it took between 15 and 20 min to reach a steady state, defined as the amount of marker infused per 10 min equaling the amount of marker recovered in the effluent per 10 min. The rats remained laying on their sides during the infusion. Additional doses of pentobarbital were administered as needed to keep the rats asleep during the experiment. At the end of the infusion, the still anesthetized rats were subjected to a rapid re-celiotomy, and the test segment was excised rapidly into an ice-cold solution of phosphate buffer solution; the mucosa was scraped with a glass slide and snap-frozen in liquid nitrogen immediately for later analysis. Samples were measured for volume, and 4.5 ml of counting cocktail (Opti-Flour, Perkin-Elmer, Shelton, CT) was added to the counting vial. Counts were obtained using dual isotope, liquid scintillation counting on a Beckman LS60000SC counter (Fullerton, CA). Samples were collected as duplicates, and the mean was used to calculate the final counts per minute per sample. Carriermediated glucose uptake was calculated as total glucose uptake ( 14 C-D-glucose) minus passive uptake ( 3 H-Lglucose) for each sample and expressed in micromoles per minute per 30-cm segment of bowel.
Preparation of Brush Border Membranes
After flushing the perfused section of the bowel with icecold perfusate, the segment was removed and placed on an ice-cold dissecting dish. The segment was cut and opened with the mucosal side up. The mucosa was scraped off the muscle layer using a glass slide. The mucosal scrapings were placed in 5 ml of ice-cold 50 mM mannitol/2 mM Tris-HCl, pH 7.1, with 0.1 mM phenylmethanesulphonyl fluoride (PMSF) and Halt protease inhibitor (Fisher Scientific, Pittsburgh, PA) and flash frozen in liquid nitrogen before storing in a −70°freezer. The sample was removed later from the freezer and thawed on ice. The sample was then passed through a 21-gauge needle to homogenize the tissue and left on ice for 10 min to allow the cells to break up. The tissue was then passed through a 22-gauge needle. Mannitol buffer with PMSF and Halt was added to a final volume of 10 ml and mixed well. The homogenized sample (1.5 ml) was transferred to a 1.5-ml Eppendorf tube for total protein analysis. The total protein sample was centrifuged at 5,000×g at 4°C for 10 min. The supernatant was kept for assay of total protein by the bicinchoninic acid (BCA) method, alkaline phosphatase measurement using p-nitrophenyl phosphate (pNPP) reagent, and for Western blotting. One molar MgCl 2 was added to the remaining sample in the 15-ml tube until the final concentration was 10 mM to precipitate all membranes except the brush border. The sample was placed on a rocker in the refrigerator for 20 min and then centrifuged at 3,000×g for 15 min at 4°C. The supernatant was transferred to another tube and centrifuged at 30,000×g for 45 min at 4°C. The pellet was resuspended in 500 μl of 100 mM mannitol/1 mM Tris-HEPES with 0.1 mM PMSF and Halt, pH 7.5, using a 21-gauge needle. The final BCA protein concentration was 2-3 μg/μl. Approximately 40 μg of protein was loaded per lane for Western blotting. Alkaline phosphatase activity was measured using pNPP reagent to confirm enrichment of alkaline phosphatase in the brush border isolation.
Western Blotting
Approximately 40 μg of protein was separated on Criterion 10% Tris-HCl gels (Bio-Rad, Hercules, CA) and transferred by semidry electroblotting to PVDF membrane (Millipore, Bedford, MA). Nonspecific binding sites on the membrane were blocked using 5% nonfat dry milk (Bio-Rad) in Tris-buffered saline (Bio-Rad) with 0.06% Tween 20 (Bio-Rad; TBS-T), and the membranes were cut into two sections at 45 kDa for separate incubation with primary antibodies. Blots were incubated overnight at 4°C with appropriate rabbit or mouse anti-rat primary antibody against transporter proteins GLUT2 (Millipore-Chemicon, Bedford, MA) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; US Biological, Swampscott, MA) diluted in 5% nonfat dry milk in TBS-T. After incubation with primary antibody, the blots were rinsed in TBS-T and then incubated in the appropriate goat anti-rabbit or goat antimouse peroxidase-conjugated secondary antibody (Sigma, St. Louis, MO). Protein bands for GLUT2 were enhanced using an Amplified Opti-4CN Detection Kit (Bio-Rad) before visualization. The bands for GAPDH did not require enhancement. All bands were visualized finally with Opti-4CN Colorimetric Detection (Bio-Rad). The visualized bands were scanned, and the band density was measured using ImageJ software. The density of each protein band of interest was expressed as a ratio to GAPDH.
Statistical Analysis
Statistical analysis was performed using paired Student's t tests to compare parametric data between groups. A p value of ≤0.05 was considered significant. All data are reported as the mean values ± standard error of the mean unless specified otherwise; n values are number of rats.
Results

Infusion Experiments
All animals tolerated the infusion experiments well. At the end of the experiment, the perfused loop was collapsed with no signs of any obstruction or visual abnormality of the segment. When rat intestine was exposed to the greater concentration of luminal glucose in vivo, active glucose absorption (carrier-mediated uptake minus passive uptake) was increased significantly. The increase in absorption was noted at 20 min and remained stable from that time point on for the rest of the infusion (Fig. 1) . Importantly, stereospecific, carrier-mediated absorption (labeled 14 C-D-glucose) increased from 2.1±0.1 to 13.9±2.9 μmol/min (p<0.001) when glucose concentration was increased from 10 to 100 mM, while passive, non-stereospecific absorption (labeled 3 H-L-glucose) increased by much less, from 0.7± 1.7 to 0.9±1.9 μmol/min per 30 cm intestinal segment (p< 0.001). The increase in absorption in the 100 mM experiments was very rapid, being evident in the first 20 min.
Inhibition of SGLT1 and GLUT2
After infusing the rat jejunum with 10 mM D-glucose for 1 h, the addition of 1.0 mM phlorizin (SGLT1 inhibitor) or phloretin (GLUT2 inhibitor) to the perfusate resulted in decrease in absorption that occurred rapidly within 20 min. After allowing 20 min for reestablishment of a steady state, carrier-mediated glucose uptake was decreased by phlorizin (SGLT1 inhibitor) from 2.5±0.2 to 0.6±0.1 μmol (p<0.02) and by phloretin (GLUT2 inhibitor) from 2.4±0.3 to 1.7± 0.2 μmol (p<0.02; Fig. 2a) . Thus, the relative contribution of glucose absorption at the lesser concentration of glucose was dependent primarily on carrier-mediated uptake by SGLT1. The transporter GLUT2 appeared, however, to be active in mediating some absorption of glucose but plays a minor role in glucose uptake at this lesser concentration of glucose.
When inhibiting SGLT1 and GLUT2 separately at the greater 100 mM concentration of luminal glucose, there was a much greater decrease in stereospecific glucose absorption. Carrier-mediated glucose uptake at 100 mM glucose infusion was decreased by phlorizin (SGLT1 inhibitor) from 9.4±2.3 to 2.0±0.9 μmol/min (p<0.01) and by phloretin (GLUT2 inhibitor) from 10.0±1.2 to 4.4±1.0 μmol/min (p<0.03; Fig. 2b ). Based on the phloretin-sensitive component, the transporter GLUT2 appeared to play the major role in glucose absorption at the greater concentration of luminal glucose. Furthermore, the phlorizin-sensitive component (SGLT1) to glucose absorption at the greater concentration of glucose appeared to be linked with GLUT2-mediated (phloretin-sensitive) absorption. The relative contribution of the phloretin-sensitive component (presumably GLUT2) to glucose absorption was 27% at 10 mM but more than double, 56%, at 100 mM (p<0.01).
Passive absorption of glucose ( 3 H-L-glucose uptake) was 0.7 ± 1.7 μmol/min at 10 mM glucose concentration, whereas it was slightly greater, 0.9±1.9 μmol/min, at the 100 mM glucose solution. The contribution of passive absorption at 10 mM glucose concentration was 25%, whereas it represented only 6% of absorption at 100 mM glucose concentration. Therefore, although there was a slight increase in the value of passive uptake at greater concentrations, there was an overall decrease in its relative contribution to glucose absorption.
Western Blot Analysis
Semiquantitative estimates of GLUT2 protein in the brush border membrane (n=6 rats at each concentration) did not Fig. 1 In vivo carrier-mediated glucose absorption at 10 and 100 mM glucose differ in the 10 mM glucose vs the 100 mM glucose (Fig. 3) . These observations show a lack of correlation with the increased carrier-mediated absorption of glucose from the 100 mM perfusions.
Discussion
While it has been assumed classically that most carriermediated intestinal absorption of glucose occurs via SGLT1, more recent, strong experimental evidence using both immunohistochemical and functional data in vivo supports the presence of the hexose transporter GLUT2 in the apical membrane of enterocytes. 17 The concept that GLUT2 only resides functionally in the basolateral membrane of enterocytes and is found in the apical membrane only in chronic states of hyperglycemia (diabetes) is disappearing slowly based on new experimental evidence. In our recent work with cell cultures of enterocyte-like cells exposed to progressively greater glucose concentrations, we showed apical translocation of GLUT2 in Caco2 and RIE-1 cell lines. 18 In our past work, we were unable to show a major role for GLUT2 in vitro, using harvested everted intestinal sleeves of rats exposed to concentrations of glucose ≥50 mM. 4 As a natural progression, we developed an in vivo model to study the absorptive properties of glucose. We designed our present in vivo model to Fig. 3 Western blot of brush border membrane of mucosal scraping. a Western blot of GLUT2 and the housekeeper gene GAPDH; b semiquantitative ratio of GLUT2 to GAPDH in brush border membrane fraction Fig. 2 a Inhibition of in vivo glucose absorption by phloretin (PT) and phlorizin (PZ) at 10 mM glucose (black arrow at 60 min represents administration of inhibitor). b Inhibition of in vivo glucose absorption by phloretin (PT) and phlorizin (PZ) at 100 mM glucose (black arrow at 60 min represents administration of inhibitor) complement our previous cell culture and in vitro data and to further explore the contribution that GLUT2 has on luminal glucose absorption under physiologic conditions as well as to investigate passive absorption of glucose during 100 mM glucose infusions in an attempt to investigate the functional status of tight junctions.
Our experiments and those of others show a marked increase in functional activity of a phloretin-sensitive component (presumably GLUT2) in response to increased concentrations of luminal glucose in the acute setting. We maintain that it is important to study this form of "acute adaptation" because it is reflective of the physiologic state after a meal containing carbohydrates. Measurements of the free luminal concentrations of glucose after a meal have been in the range of 16-28 mM. 21 This value represents the content of α-limit dextrins and disaccharides and does not take into account the local concentrations of monosaccharides at the brush border due to the activity of membranebound disaccharidases. In contrast, when the breakdown of disaccharides into sugars hydrolysis is considered, the value of free luminal glucose in the immediate vicinity of the enterocyte (the "unstirred layer") has been estimated to be as great as 300 mM. 22 Because the kinetics of SGLT1 gives a K m of around 3-6 mM, the hexose transporter SGLT1 should be saturated at glucose concentrations >25 mM; therefore, there appears to be another component of absorption that accounts for the majority of glucose absorption acutely, because only a small fraction of the monosaccharides produced from ingested meals escape from absorption at the surface of the brush border membrane. 10 When investigated, this additional component was assumed to be related to GLUT2 based on use of selective inhibitors and highly controlled imaging techniques designed to prevent translocation of GLUT2 out of the apical membrane. Our work with both D-glucose and Lglucose shows clearly that the augmented absorption of glucose is stereospecific and thus carrier-mediated. This component is not related to an increase in passive uptake by disruption of tight junctions via the solvent drag theory proposed by Pappenheimer and colleagues. Lane et al. have also published work showing that passive absorption represents a small fraction (<8%) of total glucose uptake by using L-glucose as a marker for passive absorption in unanesthetized dogs. 23 We would like to address several other theoretic possibilities to explain this augmentation in glucose uptake, although we think these to be highly unlikely. First, our kinetics suggest another "stereospecific" transporter. GLUT5, which transports fructose preferentially, is a possibility. Indeed, Rand and colleagues 24 have shown that rat GLUT5 can transport glucose, 24 but the capacity is far less than that of GLUT2, and we believe this to be highly unlikely. Second, while the phloretin might also decrease the activity of basolateral GLUT2, phloretin is not readily absorbed. Moreover, if the effect we measured was secondary to inhibition of basolateral GLUT2, then the amount of glucose we measure as "absorbed" would have to be stored in or metabolized by the enterocytes, again a highly unlikely event. Third, the absorption of glucose is relatively constant over the course of the experiment. Our work with uptake of glucose into cells in cell culture showed that the rate of uptake decreases rapidly after the first minute as the cell accumulates intracellular glucose. Thus, the glucose we measured as "absorbed" by our model would have had to accumulate in the enterocytes; we again believe this to be highly unlikely. Finally, prior work with GLUT2 null mice has shown that the ability to absorb adequate glucose to maintain health exits 25 ; while it is possible that this non-carrier-mediated process could explain the increased glucose absorption, one would not expect this process to be stereospecific nor inhibitable by phloretin.
Our use of L-glucose as a probe for paracellular permeability revealed that passive uptake of glucose accounts for 6% of total glucose absorption at the 100 mM concentration of glucose in our experiments. Solvent drag appears to play a negligible, if any, role in absorption of glucose at greater concentrations. According to the solvent drag theory, if an osmotic gradient created by the uptake of water between cells was responsible for the "diffusive" component of absorption, L-glucose should have been absorbed at a rate similar to D-glucose because of its non-stereospecificity. Interestingly, we noted a decrease in the relative contribution of passive absorption as the concentration of glucose increased. Furthermore, inhibition of GLUT2 by phloretin after perfusing in vivo rat intestine with 100 mM D-glucose showed a marked decrease in glucose absorption. This observation suggests strongly that GLUT2 is playing a major role in glucose absorption during assimilation of a meal rather than a passive process which would not have been affected by phloretin. The rapidity of the increase in carrier-mediated glucose absorption (within 20 min) suggests a posttranslational, non-genomic process being expressed as an "acute phenotypic adaptation." 26 Our work in cell culture shows this acute adaptation to occur within 5 min. 18 Given that SGLT1 inhibition (addition of phlorizin) at greater concentrations of luminal glucose also significantly decreases glucose absorption further suggests that GLUT2 activation is dependent on the activity of SGLT1. Previous investigators 20, 27, 28 and work in cell culture 18 have suggested that protein kinase C-βII is involved in the intracellular signaling pathway for activating the GLUT2 component of glucose absorption.
Protein analysis of isolated brush border membrane vesicles from the perfused jejunum using Western blot could not demonstrate any difference semiquantitatively between GLUT2 protein at the apical membrane immediately after the 10 mM vs the 100 mM glucose concentrations. Although we harvested the mucosa from the segment rapidly into the ice-cold buffer, it is possible that the GLUT2 was translocated out of the apical membrane prior to or during the isolation of the apical membrane. Alternatively, the increase in glucose absorption at 100 mM concentration may be attributable to an increase in the activity of the GLUT2 that is already expressed under baseline conditions in apical membrane. Based on the design of our current experiment, we cannot further explain these findings.
Our experimental model has several limitations that require acknowledgment. First, a constant infusion into the jejunum is not physiologic. Also, the lack of pancreatobiliary secretions may also affect the results. Second, the experiments were conducted on anesthetized rats. Third, the infusate contained glucose and not long chain carbohydrates; whether the immediate microenvironment at the apical membrane of the enterocyte reproduces the concentration of free glucose attained after a meal of complex carbohydrates is unknown. All these potential limitations must be considered when interpreting our results.
In conclusion, under the experimental conditions used, we conclude that GLUT2 appears to account for the augmented absorption of glucose from the enterocytes when the lumen of the bowel is exposed to greater concentrations of glucose, and thereby GLUT2 plays a major role in glucose absorption at greater glucose concentrations as evidenced by the effect of inhibition with phloretin. Whether this process occurs through an increase in the intrinsic activity of GLUT2 expressed basally, at the apical membrane, or through activation of an intracellular secondary messenger system (i.e., via PKC-βII) which causes rapid insertion of GLUT2 transporters to the apical membrane cannot be determined based on our data. Our data do, however, show conclusively that paracellular flow or passive absorption has a negligible effect on glucose absorption, which was thought by others in the past to represent the major route of glucose absorption postprandially.
Discussant
Dr. Stanley W. Ashley (Boston, MA): This was a terrific presentation of a well-designed and nicely conducted study examining what remains a relatively controversial hypothesis, i.e., that the GLUT2 transporter, traditionally believed to be primarily a basolateral membrane transporter, plays a role in apical glucose transport as well. Twenty years ago, this debate focused on the question of whether the apical sodium-glucose contransporter SGLT1 could explain all such transports or whether there was also some component of transport through the intercellular junctions with water, at least at high glucose concentrations. The hypothesis that GLUT2 also contributes to this is a relatively new one, and the authors have added significantly to the evidence supporting this and strengthened the argument that paracellular transport plays a minimal role. I have a couple of questions: (1) Phlorizin and phloretin seem equally effective in inhibiting transport at high glucose concentrations-does this mean that the inhibitors are less specific than we would hope or is there some interaction between the transporters? (2) Some investigators in this area have suggested that differences in species may explain some of the discrepancies between studies-do you think this is a rodent-only phenomenon or more generalizable? (3) Why have such a complex mechanism of acute adaptation? Would not it just be more simple to have the transporters there at all times rather than to insert them into the membrane only when glucose concentrations are high? Do the authors think this adaptation has any clinical significance?
Closing Discussant
Dr. Rizwan Chaudry: Thank you for the comments and excellent questions. In regard to your first question, phlorizin and phloretin at the concentrations used have been shown to be quite specific in their actions on transporters SGLT1 and GLUT2, respectively, as has been validated in several previous studies (Sarr et al. and Kellet et al.). Furthermore, in our current study, phlorizin and phloretin display significantly different effects on absorption at the 10 mM concentration of glucose, with phlorizin causing a much greater relative decrease in absorption as expected. The reason we see a similar effect on absorption (i.e., a significant decrease) with both inhibitors at the greater glucose concentration suggests that SGLT1 is necessary in GLUT2 translocation and may act as the rate-limiting step in the process; once translocated, however, GLUT2 accounted for the majority of the absorption (56%) at the greater concentration.
Although recent investigators have been studying intestinal glucose transport in vivo using a rat model, this phenomenon is not limited to this particular species. For example, a similar in vivo study was conducted in unanesthetized mongrel dogs in 1999 by Ashley et al. that showed paracellular transport to be minimal (2-5%) in its contribution to glucose absorption at supraphysiologic concentrations of glucose. Our experimental results for passive absorption at greater concentrations of glucose, although conducted in rats, paralleled what occurred in live dogs. Neither we nor to the best of our knowledge others have looked for this phenomenon in mice or other species.
Your third question, sir, is a bit more difficult to answer since we ourselves are trying to figure out the intricacies of this process. It may be that GLUT2 resides in the cytoplasm of the enterocyte and inserts to the apical membrane, or even the basolateral membrane, through an on-demand basis. As SGLT1, a high-affinity, low-capacity transporter becomes saturated, GLUT2, a low-affinity, high-capacity transporter, is rapidly available through activation of intracellular pathways involving a protein kinase C isoenzyme. The reason why GLUT2 just does not simply reside only at the apical membrane, and thus be readily available to transport glucose when luminal concentrations exceed 30 mM, could be because it may be needed in different amounts at the basolateral membrane as well, based on the amount of glucose needed to be absorbed systemically compared to the amount of glucose needed by the enterocyte itself for energy metabolism. Metabolic derangements such as hypo-or hyperglycemia may demand different amounts of GLUT2 to be readily available at certain locations of the cell Thus, a "pool" of GLUT2 deposits residing within the cytosol, being available on-demand for apical or basolateral glucose transport, makes sense.
